INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
On the May10, 2017 investor call, INC Research Holdings, Inc.
(the Company) discussed its first quarter 2017 financial results.
Through inadvertent error, the Company left out slides 36-38,
which contain second quarter 2017 guidance and a full year 2017
reconciliation. The Company has revised the investor deck to
include slides 36-38. Additionally, on slide 25, the Company is
clarifying that there are multiple clinical operational systems
available for consideration for consolidation.
A copy of the investor deck is attached hereto as Exhibit 99.1.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 | Investor presentation, dated May10, 2017. |
About INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Recent Trading Information
INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) closed its last trading session up +1.10 at 53.90 with 4,660,857 shares trading hands.
